Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.

It is a single-arm phase II clinical study of capecitabine combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
DRUG: Anlotinib|DRUG: Capecitabine
Objective Response Rate, he ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR), up to 1 year after the last patient enrolled
Progression-free survival, PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause, up to 1 year after the last patient enrolled|adverse events, Incidence and Severity of adverse events hematologic，hepatotoxicity，Incidence of hypertension，Incidence of proteinuria, approximately 1.5 years
It is a single-arm phase II clinical study of capecitabine combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer.

The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.